5 best EDC platforms for registry studies (2026)

A registry that goes quiet in year three costs you more than a stalled interventional trial ever would, since the funding is often tied to enrollment milestones you already hit, participants stop returning for follow-up, and nobody budgeted for a decade of data entry. Viedoc's EDC software is built to keep long-running registries and observational studies affordable past the first data lock, with real-time validation, flexible mid-study amendments, and integrations that sync your CTMS, labs, and existing registries without re-keying data. This comparison reviews five electronic data capture (EDC) platforms clinical teams evaluate for patient registries, natural history studies, and post-market observational programs, weighing data capture flexibility, amendment speed, compliance coverage, and integration depth.

You're not just running one study. You're maintaining a registry that outlives its original protocol, alongside observational cohorts that add sites and endpoints as funding allows, and every one of them needs to stay audit-ready for a decade or more. Add participant retention into the mix and the technology choice stops being about go-live speed and starts being about whether your platform can carry a study through years of amendments without breaking the audit trail.

Enterprise EDC platforms built for randomized interventional trials assume a fixed protocol and a defined end date, so registries end up forced into rigid visit structures that were never designed for open-ended follow-up. Commodity tools built for quick academic surveys, meanwhile, rarely carry the validation, audit trail, and compliance evidence a sponsor-funded or FDA-facing registry needs. The five platforms below were evaluated on how well they handle long-term, amendment-heavy data capture, not just how fast they launch a single fixed-arm trial.

Best EDC solutions: quick comparison

These five eClinical platforms represent the most evaluated options for registry and observational studies, reviewed across data capture flexibility, amendment speed, compliance coverage, and integration depth.

1. Viedoc

Viedoc's EDC software captures registry and observational data with real-time validation and a visual, drag-and-drop study designer, so amendments to a multi-year protocol don't require a vendor programmer. The platform has powered more than 8,000 completed studies across 75-plus countries, and 100% of Viedoc-powered studies that have faced FDA inspection have passed. For registries specifically, Viedoc's REST API and Connector service keep your CTMS, labs, and existing registries in sync, so follow-up data doesn't get re-keyed by hand.

Viedoc's RWE software is purpose-built for long-term observational studies, registries, pragmatic trials, and post-market surveillance, supporting longitudinal data collection across multiple sources without disrupting an active study when the protocol changes mid-stream. Most studies go live in eight to twelve weeks through Viedoc's professional services, with self-service teams able to launch simpler registry builds in as little as one day, and mid-study amendments landing in one to three working days rather than a multi-week change order.

Compliance holds steady across a registry's full lifecycle. Viedoc is ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA, and backed by 24/7 support across Viedoc's global offices. Viedoc SDV Manager also lets monitoring teams shift from patient-based to risk-based source data verification as a registry matures, adjusting monitoring plans by site or date without touching the eCRF design.

"Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate. As a data manager, I am using Viedoc every day for work and it has made my life so easy when it comes to exporting and reviewing data." — Khadija B., Enterprise

• Study scale: 8,000-plus studies run on Viedoc across 75-plus countries
• Build speed: Most studies go live in 8 to 12 weeks through professional services, with self-service builds live in as little as one day
• Uptime and inspections: 99.99% platform uptime; 100% of FDA-inspected Viedoc studies have passed inspection
• Compliance: 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA; ISO 27001 and SOC 2 certified
• Integration: REST API and Connector service keep CTMS, labs, and registries in sync
• Pricing: Unlimited user seats and transparent, study-based licensing with no per-seat fees

2. Medidata

Medidata offers Rave EDC, a cloud-based electronic data capture platform for capturing, managing, and cleaning clinical trial data across Phase I through Phase IV studies, including post-marketing observations and registries. Rave Companion lets sites automatically populate EDC forms with electronic health record data, reducing manual re-entry for observational programs that draw on routine care data. For long-term, pre- and post-trial patient engagement, Medidata offers myMedidata Registries as a connected module within the Medidata Platform. Rave Lite, a lighter version of Rave tailored for Phase I, Phase IV, and medical device post-market studies, is available for sponsors that don't need the full enterprise configuration. Rave connects to Medidata's RTSM, eTMF, and safety modules, so registry data sits alongside interventional trial data on the same platform for sponsors running mixed portfolios.

3. Castor EDC

Castor EDC is a cloud-based electronic data capture and clinical data management platform that combines EDC, electronic patient-reported outcomes (ePRO), and electronic consent on a single database. Castor's patient registry software supports disease registries, natural history studies, and long-term follow-up, with more than 1,000 registries run on the platform capturing over 90 million data points to date. Castor Catalyst, an add-on capability, uses AI to extract structured data from patient-shared records or site-uploaded source documents, with every extracted value reviewed by a person before it enters the registry. The platform also supports post-market clinical follow-up (PMCF) registries under the EU Medical Device Regulation, with case report forms and exports structured for technical documentation. Castor states it is compliant with FDA 21 CFR Part 11, GDPR, and HIPAA, with ISO 27001 and ISO 9001 certification.

4. Veeva Vault EDC

Veeva offers Vault EDC, a cloud application for designing clinical studies, managing protocol amendments, and capturing site and patient data without custom programming. Vault EDC is part of Veeva's broader Clinical Data Management suite, which combines it with Veeva Clinical Database and Veeva eCOA for aggregating and cleaning data from multiple sources, including third-party EDC systems. The platform includes quality controls for querying, targeted source data verification, and protocol deviation tracking, and study databases can absorb protocol amendments without downtime. Vault EDC has been used across therapeutic areas including oncology, cardiovascular, and medical device studies, and connects to Veeva's RTSM and Clinical Operations applications for sponsors standardized on the wider Vault Clinical platform. Veeva does not publish dedicated registry or natural-history-study tooling separate from its core EDC and clinical data management applications.

5. Medrio

Medrio provides a no-code electronic data capture and clinical data management system (CDMS/EDC) built for small and scaling clinical teams, spanning early-phase trials through post-market studies. The platform integrates ePRO/eCOA, eConsent, and randomization and trial supply management (RTSM) modules within the same database, with import and export APIs connecting to devices, labs, and data warehouses. Medrio markets its platform for clinical trial and registry studies specifically, citing use across pharmaceutical, biotech, medical device, and animal health programs. The company reports more than 20 years of clinical use, a site footprint spanning 30-plus countries, and studies deployed across thousands of programs. Medrio's professional services team offers database build, data management, and biostatistical support for sponsors and CROs that want to supplement an in-house team.

What to look for in EDC solutions for registry and observational studies

Support for repeating and evolving data structures

A registry protocol rarely looks the same in year five as it did at launch. New endpoints get added, follow-up windows change, and the data model has to absorb repeating events, unscheduled visits, and open-ended follow-up without a full database rebuild.

Best-in-class platforms support repeating item groups, common and unscheduled events, and recurring visit structures natively, so a data manager can add a new follow-up window without waiting on a vendor change order. If a platform treats every data point as belonging to a fixed visit number, expect friction the moment your registry outlives its original protocol.

Amendment history that survives years of protocol versions

A registry that runs for a decade will see dozens of protocol amendments, and each one has to be traceable back to exactly which data was collected under which version. That matters more for inspection readiness than build speed does, since an auditor will ask which version of the eCRF was live when a specific data point was captured.

Look for a platform that applies amendments without downtime and keeps a complete, version-linked audit trail rather than a flat change log. A registry that can't reconstruct its own history at each amendment point creates real risk at the point of regulatory submission or inspection, years after the original build.

Integration depth with EHR, labs, and existing registries

Much of a registry's value comes from data that already exists somewhere else, whether that's an electronic health record, a local lab system, or a national disease registry your sponsor already reports into. Building a registry that only accepts manually entered data ignores the sources that already hold the most complete picture of a patient's history.

Best-in-class platforms offer open APIs and CDISC-compliant export formats that connect cleanly to CTMS, EHR, and lab systems, plus a route for structured extraction from source documents when a direct feed isn't available. A registry with no integration path beyond manual entry burdens sites for years, not just at launch, and that burden is usually what drives sites to stop reporting.

Participant retention tooling for multi-year follow-up

Registries and long-term observational studies live or die on whether participants keep reporting past the first year. A platform that only supports site-based data entry puts the entire retention burden on already-stretched site staff.

Look for electronic patient-reported outcomes (ePRO) that participants complete on their own devices, automated reminder schedules, and remote consent tools that support re-consent when a multi-year protocol changes. Platforms without direct-to-patient reporting options tend to see follow-up compliance drop sharply once participants stop visiting a site regularly.

How to choose the right EDC solution for registry and observational studies

Step 1: Define the study's real lifespan, not its funded phase

Map out how long the registry or observational program is realistically expected to run, including any post-market follow-up obligations, not just the currently funded phase. A platform evaluated only against a two-year budget cycle will show cracks the moment that funding gets renewed for another decade.

Step 2: Assess how much of your data already lives outside the EDC

Inventory the EHR systems, lab feeds, and existing registries your study already draws from or reports into, since that determines how much integration work sits ahead of you. A platform with strong build speed but weak API support can still leave your team manually reconciling data every quarter.

Step 3: Evaluate who owns amendments after year one

Ask whether your own data managers can push protocol amendments and add follow-up windows, or whether every change routes through a vendor programmer with a queue. Vendor dependency is a minor annoyance in a six-month trial and a structural cost in a registry that runs for years.

Step 4: Scrutinize retention and re-consent support specifically

Registries lose participants gradually, not all at once, so evaluate ePRO, reminder, and re-consent capabilities as a distinct line item rather than folding them into a general usability review. A platform that scores well on site-facing usability can still lack the direct-to-patient tools that keep a registry populated past year two.

Step 5: Choose a platform built for the shape of the study you're actually running

If your registry falls under EU MDR post-market surveillance or Japan's PMDA requirements, factor that in directly. Viedoc's post market surveillance software is built specifically for these programs, and pairs with the same EDC platform your team already uses for interventional studies, so a mixed portfolio doesn't mean switching tools for every study type. If you're ready to see how it fits your registry, you can book a demo with Viedoc's team.

Frequently asked questions

What is the best EDC platform for registry and observational studies?

Viedoc's EDC software is the strongest fit for most registries and observational programs, combining real-time validation, repeating data structures, and REST API integrations that keep CTMS, labs, and existing registries in sync, backed by 8,000-plus completed studies across 75-plus countries. Medidata's Rave EDC is a strong alternative for large sponsors already standardized on the Medidata Platform who want myMedidata Registries and Rave Lite in the same ecosystem. Castor EDC is worth evaluating for registries that lean heavily on AI-assisted extraction from patient-shared records or source documents.

What should I look for when choosing an EDC platform for a patient registry?

Prioritize support for repeating and evolving data structures, since a registry's data model changes as the protocol matures over years rather than months. Look closely at how amendments are applied and whether the audit trail stays version-linked, how deep the platform's integrations run with EHR and lab systems, and whether participants can report outcomes remotely without a site visit. Build speed matters far less for a registry than it does for a fixed-arm interventional trial.

How long does it take to build and deploy a registry study on a modern EDC platform?

Timelines vary by platform and complexity, but most EDC vendors report study builds in the range of a few weeks to around three months depending on protocol complexity and whether the sponsor self-builds or uses professional services. Simpler registry builds can go live faster through self-service, drag-and-drop configuration, while complex, multi-arm observational designs typically take longer. The bigger factor for registries specifically is how quickly the platform can absorb amendments after go-live, not the initial build time alone.

Can an EDC platform integrate with existing registries, labs, and EHR systems?

Most modern EDC platforms offer some form of open API or CDISC-compliant export, but the depth of that integration varies significantly between vendors. Platforms built with a REST API and dedicated connector services can sync data with CTMS, lab systems, and other registries without manual re-entry, while some platforms rely more heavily on manual export and import processes. This matters more for registries than for short interventional trials, since a registry accumulates external data continuously over years rather than at a handful of scheduled visits.

What compliance certifications matter most for a long-running observational study or registry?

FDA 21 CFR Part 11, ICH GCP, and GDPR form the baseline for most global registries, with EU Annex 11 and HIPAA relevant depending on the study's geography and data types. Platform-level certifications such as ISO 27001 and SOC 2 speak to the vendor's information security posture, which matters over a study that will hold sensitive patient data for a decade or more. For MedTech-sponsored registries under EU MDR, look specifically for platforms with case report form structures and export formats built for post-market clinical follow-up documentation.

How does Viedoc's registry and observational study support compare to Medidata's myMedidata Registries?

Viedoc's RWE software is built as a core use case across its EDC platform, supporting registries, natural history studies, and post-market surveillance within the same modular license used for interventional trials. Medidata's myMedidata Registries is a dedicated module within the broader Medidata Platform, aimed primarily at large sponsors already using Rave EDC for their interventional trial portfolio. The right fit depends largely on whether your organization needs a standalone, right-sized registry platform or a registry module layered onto an existing enterprise Medidata deployment.

Making the right EDC choice for registry and observational studies

The EDC platforms reviewed here share a common baseline of cloud delivery, audit trails, and regulatory compliance, but they diverge sharply in how they handle data that accumulates over years rather than months. The global eClinical software market is estimated at more than $11 billion in 2025, growing at roughly 14% annually, and a meaningful share of that growth is coming from registries, observational studies, and other post-market programs that outlast a traditional trial timeline.

Match the platform to your organization's actual profile: study complexity, how much data already lives in outside systems, how many people need to make amendments without a vendor programmer, and where your studies are geographically regulated. Sponsors and CROs in the US tend to weight build speed and cost predictability more heavily, while EMEA and APAC-based teams often weight compliance credentials and long-term vendor stability first.

Switching EDC platforms mid-registry carries a validation and re-consent burden that a switch mid-trial doesn't, which makes the platform decision at the outset worth more scrutiny than it gets in a standard interventional trial evaluation.

Why Viedoc is the best EDC choice for registry and observational studies

Viedoc's EDC software is built to carry a registry or observational study through years of amendments without forcing a rebuild, backed by more than 8,000 completed studies across 75-plus countries and 99.99% platform uptime. The platform's REST API and Connector service keep your CTMS, labs, and existing registries synced automatically, so follow-up data doesn't sit in someone's inbox waiting to be re-entered by hand.

Operationally, Viedoc is built for self-sufficiency. Your data managers can add follow-up windows, adjust repeating data structures, and push protocol amendments in one to three working days, without routing every change through a vendor queue. Pricing stays transparent and study-based, with unlimited user seats included as standard, so a registry that grows its site count over a decade doesn't come with a growing per-user bill.

Compliance holds up over the full lifecycle a registry needs. Viedoc is ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA, and 100% of Viedoc-powered studies that have faced FDA inspection have passed. Founded in 2003, Viedoc has more than 20 years of clinical trial deployment behind it.

If you're weighing platforms for a registry or observational program that needs to hold up for years, not just get through the next data lock, book a demo or request a proposal and Viedoc's team will walk through build speed, integration depth, and compliance coverage in the context of your own study.